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Abstract: Cancer cachexia is a multilayered syndrome consisting of the interaction between tumor
cells and the host, at times modulated by the pharmacologic treatments used for tumor control.
Key cellular and soluble mediators, activated because of this interaction, induce metabolic and
nutritional alterations. This results in mass and functional changes systemically, and can lead
to increased morbidity and reduced length and quality of life. For most solid malignancies,
a cure remains an unrealistic goal, and targeting the key mediators is ineffective because of
their heterogeneity/redundancy. The most beneficial approach is to target underlying systemic
mechanisms, an approach where the novel non-peptide ghrelin analogue anamorelin has the
advantage of stimulating appetite and possibly food intake, as well as promoting anabolism and
significant muscle mass gain. In the ROMANA studies, compared with placebo, anamorelin
significantly increased lean body mass in non-small cell lung cancer (NSCLC) patients. Body
composition analysis suggested that anamorelin is an active anabolic agent in patients with NSCLC,
without the side effects of other anabolic drugs. Anamorelin also induced a significant and meaningful
improvement of anorexia/cachexia symptoms. The ROMANA trials have provided unprecedented
knowledge, highlighting the therapeutic effects of anamorelin as an initial, but significant, step
toward directly managing cancer cachexia.
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1. Cancer Cachexia, Ghrelin, and Anamorelin
Cancer cachexia is a multifactorial condition, usually defined as ≥5% weight loss during the six
months prior to screening, or body mass index (BMI) <20 kg/m2 [1] in the presence of uncontrolled
cancer, and is not reversible by nutrition alone. The etiology of cancer cachexia is not yet fully
clarified; central features comprise anorexia, reduced food intake, and increased systemic inflammation
(C-reactive protein levels above upper limits of normal) [2,3]. Pathophysiologic manifestations of cancer
cachexia include a negative protein and energy balance, sarcopenia [4], and abnormal metabolism
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and progressive functional impairment [1]. Thus, relative to patients without cachexia, patients with
cancer cachexia frequently experience greater symptom burden, reduced tolerance and responsiveness
to chemotherapy, decrease in quality of life (QOL), and shortened survival time [5–8]. Weight loss and
BMI are independent prognostic factors in patients with cancer and associated cachexia. The more
accentuated the weight loss and the more rapid the decrease in BMI, the stronger the correlation with
higher morbidity and mortality [9].
This debilitating condition develops in patients with various types of cancer, with a prevalence of
50–80%, depending on tumor type [10]. Patients with advanced non-small cell lung cancer (NSCLC)
and cachexia also present with respiratory complications that compound the symptom burden of
cachexia, including debilitating fatigue [11]. In these patients, cancer cachexia reaches a prevalence of
60% over the course of the disease [12].
There is no standard of care for the management of cancer cachexia. The ideal drug for cancer
cachexia would improve appetite, food intake, and sense of well-being, while also attenuating muscle
protein breakdown [13] and stimulating anabolism to increase lean body mass (LBM) and body weight
without unacceptable side effects. Currently used drugs, such as corticosteroids and progestational
agents, have been shown to enhance appetite and increase body weight [14–16], but have little,
if any, positive effect on LBM and skeletal muscle [17,18]. Increases in body weight with these agents
are mainly led by increases in fat mass (FM) and water retention, with weight gain and appetite
stimulation reportedly transient and disappearing within weeks. In addition, both corticosteroids
and progestational agents are associated with substantial toxicity. The most notable problem is
that corticosteroids are catabolic and, as such, can contribute to skeletal muscle wasting [13,19,20].
This is the opposite of the desired effect and suggests that appetite stimulation in this setting
comes at a high health cost. For corticosteroids, the long-term adverse events (AEs) include insulin
resistance, fluid retention, steroidal myopathy, skin fragility, adrenal insufficiency, immunosuppression,
and psychotropic effects [21,22]. For progestational agents, prolonged administration increases the
risk of thromboembolic events [23,24], adrenal insufficiency [25], fluid retention, hypogonadism,
and death [23].
International guidelines committees, including the European Society for Clinical Nutrition and
Metabolism, the European Palliative Care Research Collaborative, and the National Comprehensive
Cancer Network, consider reduced food intake and metabolic imbalances as central to cancer
cachexia, and their treatment recommendations focus primarily on maintaining body weight [22,26,27].
Guidelines suggest a multimodal approach to treating cancer cachexia that comprises nutritional
intervention, physical exercise to support maintenance of function [28,29], and pharmacologic
treatment, although very limited data concerning the efficacy of this proposed strategy are currently
available [30].
Appetite-Improving Drugs: Ghrelin and Ghrelin Agonists
Ghrelin, a peptide gastric hormone, is the endogenous ligand of the growth hormone (GH)
secretagogue receptor 1a and stimulates multiple pathways that regulate appetite, LBM, body weight,
and metabolism [31,32]. In patients with advanced cancer, ghrelin has been shown to stimulate GH,
significantly enhance appetite, and regulate energy balance, with minimal reports of drug-related
AEs [33–35]. However, the parenteral administration of ghrelin, combined with its short half-life
(less than 30 min), has considerably limited its clinical utility.
Anamorelin is a novel, orally active, highly selective non-peptide ghrelin analogue that has
been shown to simultaneously target multiple components of cancer cachexia, including appetite,
body composition, adipose tissue metabolism, energy expenditure, and inflammation [36,37].
The international, randomized, double-blind, placebo-controlled phase 3 trials ROMANA 1
(NCT01387269) and ROMANA 2 (NCT01387282) assessed the efficacy and safety of anamorelin
in patients with advanced NSCLC and cachexia over a 12-week period [38] (Table 1). Anamorelin
treatment was well tolerated and, compared with placebo, significantly increased the co-primary
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endpoint of LBM in both ROMANA 1 (median increase of 0.99 kg [95% confidence interval (CI):
0.61, 1.36] compared with median loss of 0.47 kg [95% CI: −1.00, 0.21]; p < 0.0001) and ROMANA 2
(0.65 kg gain [95% CI: 0.38, 0.91] compared with median loss of 0.98 kg [95% CI: −1.49, −0.41];
p < 0.0001), although it had no significant effect on the other co-primary endpoint, handgrip strength.
In both studies, anamorelin versus placebo significantly improved total body weight (ROMANA
1: 2.20 ± 0.33 kg vs. 0.14 ± 0.36 kg, p < 0.0001; ROMANA 2: 0.95 ± 0.39 kg vs. −0.57 ± 0.44 kg,
p < 0.0001), as well as LBM, FM, appendicular LBM, and total body mass [38]. These results are in
line with anamorelin’s properties as a non-peptide ghrelin analogue. Anorexia/cachexia symptoms
and concerns of patients were also significantly improved following anamorelin treatment (mean
change in the Functional Assessment of Anorexia/Cachexia Therapy [FAACT] Anorexia/Cachexia
Subscale [A/CS] [39] domain score, ROMANA 1: 4.12 ± 0.75 vs. 1.92 ± 0.81, p = 0.0004; ROMANA 2:
3.48 ± 0.94 vs. 1.34 ± 1.03, p = 0.0016) [38,40].
Table 1. Major results of the ROMANA 1 and ROMANA 2 studies.
Parameter
Anamorelin vs. Placebo
ROMANA 1 ROMANA 2
Median LBM. kg 0.99 vs. −0.47 0.65 vs. −0.98
Median HGS, kg −1.10 vs. −1.58 –1.49 vs. −0.95
Mean body weight, kg 2.20 vs. 0.14 0.95 vs. −0.57
Median FM, kg 1.21 vs. −0.12 0.77 vs. 0.09
Median aLBM, kg 0.87 vs. 0.30 0.62 vs. −0.21
Mean FAACT A/CS domain score 4.12 vs. 1.92 3.48 vs. 1.34
aLBM, appendicular lean body mass; FAACT A/CS, Functional Assessment of Anorexia/Cachexia Therapy
Anorexia/Cachexia Subscale; FM, fat mass; HGS, handgrip strength; LBM, lean body mass; TBM, total body mass.
Participants with an Eastern Cooperative Oncology Group performance status ≤2 who completed
dosing in either of the two original 12-week trials could enroll in a 12-week safety extension study,
ROMANA 3 (NCT01395914). Over the ROMANA 3 treatment period, anamorelin continued to
be well tolerated and significantly increased body weight, when compared with placebo, over the
entire 24-week period (least-squares mean change ± standard error: 3.1 ± 0.6 kg vs. 0.9 ± 0.7 kg;
p < 0.0001) [41]. Improvements in anorexia were also observed over the 24-week period (significant
differences with anamorelin vs. placebo at weeks 3, 6, 9, 12, and 16 [p < 0.05]) [41].
In the clinical setting, a noteworthy response to nutritional support is observed in patients with
severe undernutrition (BMI <20 kg/m2 at baseline) [1,18,42]. A retrospective post hoc analysis of
pooled efficacy data in different subgroups of patients from ROMANA 1 and ROMANA 2 found that,
compared with placebo, anamorelin led to greater improvements in body weight in patients with
BMI <20 kg/m2 at baseline (treatment difference with anamorelin vs. placebo: 3.09 kg [95% CI: 1.73,
4.44]; p < 0.001). Importantly, anamorelin’s effect on body weight was even more pronounced in these
low-BMI patients than in the pooled overall population (treatment difference: 2.19 kg [95% CI: 1.56,
2.83]; p < 0.001) [43].
The proportion of patients achieving ≥5% increase in body weight following anamorelin treatment
was also assessed in the pooled overall population and in patients with BMI <20 kg/m2 at baseline.
This threshold was chosen on the basis of the consideration that an unintended weight loss of ≥5%
represents one of the diagnostic criteria for cancer anorexia/cachexia [1]. Interestingly, 34.1% of patients
in the overall efficacy population and 47.3% of patients with BMI <20 kg/m2 at baseline benefited
from anamorelin [43], compared with 13.4% and 17.4%, respectively, in the placebo arm. These results
highlight anamorelin’s capacity to mimic ghrelin’s body weight-enhancing properties [34,35].
Patients with severe weight loss are an at-risk population [44] that is extremely difficult to treat [45].
As such, these results are of crucial clinical importance, as they demonstrate that anamorelin is highly
effective in severely underweight patients who are at the greatest risk from cancer cachexia.
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2. Relevance of Improvement in LBM, FM, and Handgrip Strength
2.1. Relevance of Improvement in LBM
The loss of LBM and the accompanying decline in physical function are cardinal features of cancer
cachexia. An assessment approach that considers body composition is important for patients with
lung cancer and cachexia, as neither body weight [46,47] nor BMI [48] are strongly correlated with
LBM or skeletal muscle.
A decline in LBM is observed as a natural feature of aging, with LBM reported to decrease from
50% of total body weight in healthy young adults to about 25% by the age of 75–80 years [49,50].
The natural decline typically commences in the sixth decade of life and is very gradual, with a mean
loss of only 6–8% per decade, which equates to about 2.5–2.8 kg, depending on stature [51]. In patients
with cancer, this decline is accelerated. Longitudinal studies report LBM loss between 0.14 and 0.20 kg
per month [52] and, in patients with lung cancer, up to 6% over 100 days [53]. In the year preceding
death, only 15% of patients achieve a measurable gain in muscle mass without intervention when
assessed serially; muscle mass loss is more evident in patients with progressive compared with stable
disease and is much more common in patients within three months of death [54].
LBM loss leads to reduced skeletal muscle function and performance (Figure 1). LBM has a role in
whole-body metabolism, given that skeletal muscle forms the body’s dominant source of protein. Loss
of LBM depletes this storage, diminishes physiologic reserves, and reduces the ability to withstand
insult, particularly in response to stress [55,56]. This may explain why patients with low LBM tend to
tolerate chemotherapy poorly, as the low muscle mass may lower the capacity for metabolizing and
clearing drugs, leading to enhanced drug toxicity [57]. Across multiple cohort studies, patients with
low LBM experience more severe or dose-limiting toxicities and earlier cessation of chemotherapy
compared with those with relatively higher LBM [22]. Recent examples include cohorts of patients with
newly diagnosed lung cancer (N = 134) [58], patients commencing first- or second-line chemotherapy
(N = 200) [59], and patients scheduled for any anticancer treatment (N = 80) [57]. These findings are
not limited to cancer type or anticancer drug, as low LBM is shown to predict toxicity in patients
with various types of cancers treated with sorafenib [60], sunitinib [61], or afatinib [62]. Conversely,
maintaining or gaining muscle mass during chemotherapy has been independently associated with
reduced mortality, which may reflect stabilization of the disease, but also successful management of
cancer cachexia [63]. Low LBM and low muscle mass have been associated with higher mortality in
several studies with small- to medium-sized cohorts [22,58], although there is variation in the cutoff
points used, most of which are generated retrospectively, and these studies generally lack a validation
cohort [64].
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Figure 1. Clinical relevance of low LBM. ADL, activities of daily living; LBM, lean body mass.
Muscle dysfunction in cancer cachexia is driven by systemic inflammation and involves the
peripheral and respiratory muscles. In patients with advanced lung cancer (N = 40), lower limb
and inspiratory muscle strength are independently positively associated with whole-body exercise
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performance (r = 0.44 and 0.39, respectively) [65]. Conversely, loss of peripheral muscle results in
buildup of waste products perceived as local muscle soreness or fatigue. These waste products
also provide an afferent feedback to the respiratory centers to increase the rate of breathing [66].
With impaired respiratory muscle capacity, the body cannot respond appropriately to these afferent
messages, and the resultant efferent–afferent mismatch is responsible for chronic breathlessness [67,68].
In a longitudinal study tracking muscle mass in advanced cancer (N = 368), gains in muscle mass
were associated with improved physical function and ability to eat, better symptom control, and better
response to anticancer treatment [54].
2.2. LBM and Handgrip Strength Responses to Interventions
The LBM response to various interventions in patients with advanced cancers is highly indicative
of their efficacy and has been used as a primary outcome measure in a number of clinical trials,
as described below.
In the two ROMANA trials, anamorelin treatment led to significant increases in LBM and an
impressive arrest of ongoing weight loss in both the overall population [38] and in patients with BMI
<20 kg/m2 at baseline, when compared with placebo (1.25 kg vs. −0.46 kg; p < 0.001). These results
highlight anamorelin’s properties as a non-peptide ghrelin analogue to regulate appetite and body
weight in patients with advanced cancer [34,35]. Considering that patients with advanced cancer
undergo a LBM loss of 0.14–0.20 kg per month [52], the 1 to 2 kg increase observed after the 12-week
anamorelin treatment is clinically relevant, and similar to that reported for lung cancer patients
recovering from resection surgery and following high-intensity exercise training [69]. These results further
highlight anamorelin’s efficacy and utility in a patient population with a rapidly deteriorating status
due to cancer and associated malnutrition.
Anamorelin was associated with a numerically lower reduction in the co-primary endpoint
of handgrip strength, when compared with placebo, although the results did not reach statistical
significance (−1.10 kg [95% CI: −1.69, −0.40] vs. −1.58 kg [95% CI: −2.99, −1.14]; p = 0.15). This lack
of significance may be explained, in part, by the continually worsening condition of these patients with
advanced disease, the absence of a training program for these small muscles coupled with the volitional
nature of testing that draws on neuromuscular performance, as well as the low mechanical quality of
muscle that has been observed in patients with cancer cachexia [70,71]. Moreover, the magnitude of
increase in LBM necessary to achieve a detectable shift either in muscle strength or that is discernible
to patients is currently unknown. Arguably, maintenance or improvement of function, for example,
daily physical activity or level of disability, may provide a better “real-world” measure of the impact
of treatments to manage cancer cachexia.
The ACT-ONE trial was a randomized, double-blind, placebo-controlled phase 2 trial that
evaluated the efficacy of two different doses of espindolol, an MT-102 anabolic/catabolic transforming
agent, in 87 patients with cachexia and stage III/IV NSCLC or colorectal cancer [72]. A statistically
significant increase in LBM, the primary efficacy endpoint, was seen after treatment with 10 mg
twice-daily (b.i.d.) espindolol compared with placebo (1.76 kg vs. 0.57 kg; p = 0.012). Handgrip strength
was also significantly improved after administration of 10 mg b.i.d. or 2.5 mg b.i.d. espindolol [72].
The change in handgrip strength following high-dose espindolol was greater than changes observed
in stair-climbing power or the 6 min walking test. ACT-ONE was a small phase 2 trial with a
heterogeneous patient population, so these results require further confirmation in a phase 3 trial.
The POWER trials were two identically designed randomized, multicenter, multinational
phase 3 studies to assess the efficacy of the non-steroidal selective androgen receptor modulator
enobosarm for prevention and treatment of muscle wasting in patients with NSCLC initiating first-line
chemotherapy [73]. In both trials, enobosarm compared with placebo significantly increased LBM
(POWER 1: 0.41 vs. −0.92 kg, p = 0.0002; POWER 2: 0.47 vs. −0.37 kg, p = 0.0111) at day 84 [74].
However, enobosarm’s effect on physical function was less prominent, as no significant improvements
were observed in either of the studies in the percentages of patients gaining ≥10% improvement in
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stair-climbing power at day 84 (responders; POWER 1: 29.4% vs. 24.2%, p = 0.315; POWER 2: 19.5% vs.
24.8%, p > 0.05) [74,75]. The co-primary efficacy endpoints of these trials, changes in LBM and physical
function (assessed as stair-climbing power) at day 84, were defined after extensive feedback from the
United States Food and Drug Administration (FDA). The FDA-informed analysis plan described that
LBM, measured at day 84, equal to or higher than the initial LBM of patients is translated into response
to treatment [73], citing that “prevention is important, as muscle wasting begins before outward
clinical signs or symptoms, including overt weight loss” [76]. However, whether physical function
tests (e.g., handgrip strength, sit-to-stand, stair-climbing power) are suitable surrogate measures of
strength in patients with advanced cancer and cachexia still needs to be established [77].
In summary, LBM represents a useful tool for assessing the efficacy of pharmacologic interventions
for cancer cachexia. Anamorelin has a clinically meaningful effect on body weight and LBM, and the
ROMANA studies are among the most relevant in humans to demonstrate a drug’s capacity to reverse
loss of lean tissue and LBM in the setting of advanced cancer.
2.3. Relevance of Improvement in FM
In patients with cancer cachexia, nutritional therapy to satisfy protein and caloric needs is
usually inadequate [54]. By definition, nutritional therapy alone cannot reverse the effects of cancer
cachexia [22,78]. One of the underlying consequences, and one of the main characteristics of cancer
cachexia, is loss of FM in addition to LBM. FM represents a central location for energy storage, and a
diminished accumulation of fatty tissue cannot be reversed by nutritional intervention alone [79],
indicating that patients with FM loss have a profoundly altered metabolism.
In the ROMANA trials, anamorelin showed significant benefits in terms of FM, in addition to
body weight and LBM (muscle), appendicular LBM, and total body mass. Anamorelin treatment
significantly increased FM in both trials, when compared with placebo (ROMANA 1: 1.21 kg [95% CI:
−0.2, 2.8] vs. −0.12 kg [95% CI: −0.1, 1.0], p < 0.0001; ROMANA 2: 0.77 kg [95% CI: −0.8, 2.4] vs.
0.09 kg [95% CI: −1.1, 1.1], p = 0.012) [38]. Notably, the initial observed increase in FM continued
beyond week 6 to week 12, suggesting that the response in terms of FM might not have reached a
plateau by the end of the study period. These results were confirmed by a pooled post hoc analysis
of efficacy data from ROMANA 1 and ROMANA 2. In this large data set (N = 829), the increase in
FM concurred with that reported for the individual trials [80]. Considering that each kilogram of
fat contains approximately 9000 kcal, and the average duration of treatment was 12 weeks, which
suggests a net positive energy balance of approximately 100 kcal per day. The daily deficit in total
energy expenditure of patients with advanced cancer is approximately 100–200 kcal per day [81].
Consequently, the effects of anamorelin on energy balance may be considered clinically meaningful
(a net daily difference of more than 200 kcal), as an additional 100 kcal per day would allow most
patients to reach normal levels of physical activity or exercise, in line with the American College of
Sports Medicine’s recommendations [82].
The observed improvements in FM in anamorelin-treated patients, coupled with improvements in
body weight and body composition parameters, suggest a positive effect of anamorelin on food intake.
Unfortunately, food intake was not measured in the ROMANA trials. As such, body composition,
as measured by changes in the FM and LBM parameters, was used as an endpoint to estimate the
influence of anamorelin on energy and protein balance over 12 weeks. This approach was validated by
Lieffers et al. [83], who estimated the contributions of organ and tumor mass to whole-body energy
demands by monitoring changes in body composition of patients with advanced colorectal cancer
and cachexia.
Nevertheless, it remains unclear whether anamorelin improves muscle strength and physical
function, or whether such improvement should be required to support the value of increased LBM
and FM. Other patient-reported effects might help determine treatment value.
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3. Patient-Reported Benefits of Anamorelin: The Anorexia/Cachexia Scale
Patients’ emotional well-being and QOL are severely compromised by cancer cachexia and its
associated symptoms [39,84–86]. Hence, patient-reported measures, which can provide direct evidence
of social and clinical outcomes [8] and have independent prognostic value [87], are necessary to assess
items of relevance in patients with anorexia/cachexia [88].
The Functional Assessment of Chronic Illness Therapy (FACIT) family of questionnaires is
designed to assess QOL. They are among the best-validated instruments for use in patients with
cancer [84,89]. The Functional Assessment of Cancer Therapy-General (FACT-G) [90] is the core
instrument, and contains four domains: physical, functional, emotional, and social well-being.
The FAACT assessment tool combines the FACT-G with the A/CS [39] and has been validated in
patients with anorexia/cachexia and advanced cancers [91], including NSCLC [8,39]. The FAACT
questionnaire contains the 12-item A/CS domain that specifically addresses anorexia/cachexia
(Table 2), and is the ideal tool to measure the complex phenomenon of appetite/eating [92], as the
questions not only evaluate cancer anorexia/cachexia symptoms and concerns including appetite,
early satiety, and other gastrointestinal symptoms, but also assess patient concerns related to
weight/appearance, family interactions, and general health [39]. A treatment specific for cancer
anorexia/cachexia can be expected to show an effect on the A/CS domain due to its specificity, but not
necessarily on the more general FACT-G. Moreover, a treatment specific for targeting the ghrelin
receptor can also be expected to show an effect on the A/CS domain, as this domain contains items
related to appetite, eating, and weight loss, which is more proximal to the mechanism of action
compared with the general items of the FACT-G.
Table 2. The 12 items of the FAACT A/CS domain.
I have a good appetite
The amount I eat is sufficient to meet my needs
I am worried about my weight
Most food tastes unpleasant to me
I am concerned about how thin I look
My interest in food drops as soon as I try to eat
I have difficulty eating rich or “heavy” foods
My family or friends are pressuring me to eat
I have been vomiting
When I eat, I seem to get full quickly
I have pain in my stomach area
My general health is improving
A/CS, Anorexia/Cachexia Subscale; FAACT, Functional Assessment of Anorexia/Cachexia Therapy. Each statement
is rated for a period of the past seven days, and is answered on a five-point rating scale ranging from “not at all” to
“very much” (www.facit.org).
A recent survey among 95 patients with advanced NSCLC compared QOL and anorexia/cachexia
symptom burden in patients with and without considerable weight loss on survey initiation [93].
Considerable weight loss was defined as weight loss >5%, or weight loss >2% in patients already
showing depletion according to current body weight and height (BMI <20 kg/m2) or skeletal
muscle mass (sarcopenia). Patients with considerable weight loss had a significantly lower overall
QOL (European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life
Questionnaire for palliative cancer care patients [QLQ-C15-PAL] score: 55.2 vs. 66.9; p = 0.03);
worsened anorexia/cachexia symptoms and concerns (FAACT A/CS domain score: 30.7 vs. 36;
p = 0.001); and worse fatigue (64.8 vs. 49.1; p = 0.007), nausea (19.5 vs. 9.2; p = 0.009), and appetite
loss (41.0 vs. 23.9; p = 0.004). Significantly more patients who lost weight reported moderate or high
distress levels than patients whose weight was stable (71% vs. 38%; p = 0.007). For patients with
considerable weight loss, the most frequently reported symptoms that had the greatest impact on their
lives were changes in food taste (38%), fatigue (38%), decrease in appetite (33%), and early satiety
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(14%) [93]. Notably, food taste, appetite, and early satiety are all items captured in the questions on the
A/CS domain, highlighting its utility as an independent tool to measure symptoms and concerns in
patients with advanced cancer and cachexia.
When using the FAACT questionnaire and A/CS domain to assess anorexia/cachexia, validated
cutoff values (thresholds) for defining patients with anorexia/cachexia and those who respond to
treatment are useful. Thresholds chosen to define a responder patient should be determined according
to the change in the A/CS domain necessary to establish an important difference (ID) in outcome.
Using an anchor-based approach with performance functional status as the anchor [39], a change of
four points in the A/CS domain score can be considered an ID. This four-point responder threshold
was also confirmed when assessing the psychometric properties of A/CS in NSCLC patients who
participated in the ROMANA program using both anchor- and distribution-based approaches [94],
and can thus be viewed as a starting point for consideration in any study.
In both ROMANA 1 and ROMANA 2, anamorelin, when compared with placebo, significantly
improved anorexia/cachexia symptoms and concerns of patients over the 12-week study period [38,40].
Significant improvements were noted by week 3 and were evident throughout the entire study period.
These positive results were confirmed in a post hoc analysis performed in 829 patients from the
ROMANA 1 and ROMANA 2 trials [71], where significant improvements in the A/CS domain score
were observed over 12 weeks with anamorelin when compared with placebo (treatment difference:
1.84 [95% CI: 0.50, 3.18]; p = 0.007). While this comparison of group means between treatment arms aids
in determining statistical significance, recent practice for evaluating clinical meaningfulness focuses
on interpretation of treatment benefit at the individual level (i.e., responder analysis). As such, in the
pooled overall population, a significantly higher proportion of patients achieved a clinically meaningful
improvement in the A/CS domain score following anamorelin than following placebo (50% vs. 37%;
p < 0.001) [71]. In patients with BMI <20 kg/m2 at baseline treated with anamorelin, the A/CS
improvement rate (59%) was higher than in the overall patient population, whereas the placebo arm
had a rate similar to the overall population (34%). These results further highlight anamorelin’s efficacy
in patients with severe weight loss.
Anamorelin also led to improvements in several individual items of the A/CS in the overall
population (Table 3). A retrospective analysis showed that, in patients with BMI <20 kg/m2 at
baseline, the effect of anamorelin versus placebo on several single items of the A/CS domain was more
pronounced than in the overall population. The two items most changed in the overall population
(“I am concerned about how thin I look” and “I am worried about my weight”; Table 2) reflect important
concerns expressed by patients due to the physical and psychosocial effects of cancer-associated
anorexia and weight loss, which are ameliorated by anamorelin treatment. Importantly, the reported
improvements in symptom burden were consistently maintained throughout the 12-week safety
extension study ROMANA 3 [41,95]. Over the entire 24-week treatment period, anamorelin led to
improvements in anorexia/cachexia symptoms, with significant treatment differences at weeks 3, 6, 9,
12, and 16 (p < 0.05). A post hoc analysis confirmed these results and reported that, over the entire
24-week treatment period, patients receiving anamorelin had a larger mean increase in their A/CS
domain score compared with placebo (4.5 [95% CI: 2.7, 6.3] vs. 3.2 [95% CI: 1.0, 5.2]).
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Table 3. Anamorelin treatment effect size on the 12 individual items of the FAACT A/CS domain.
Individual Item








Effect Size p Value
I am concerned about how
thin I look
0.41
(0.218, 0.601) 0.317 0.000
0.53
(0.083, 0.976) 0.375 0.018
I am worried about my
weight
0.29
(0.086, 0.493) 0.213 0.005
0.37
(–0.091, 0.831) 0.253 0.110
My family or friends are
pressuring me to eat
0.23
(0.025, 0.454) 0.163 0.029
0.72
(0.253, 1.186) 0.424 0.002
The amount I eat is sufficient
to meet my needs
0.16
(−0.011, 0.331) 0.139 0.064
0.54
(0.168, 0.911) 0.451 0.005
Most food tastes unpleasant
to me
0.16
(−0.036, 0.356) 0.117 0.117
0.39
(−0.072, 0.852) 0.254 0.109
I have pain in my stomach
area
0.15
(−0.001, 0.301) 0.149 0.046
0.36
(−0.057, 0.777) 0.273 0.085
I have a good appetite 0.12(−0.063, 0.303) 0.094 0.210
0.31
(−0.115, 0.735) 0.218 0.167
My interest in food drops as
soon as I try to eat
0.11
(−0.075, 0.295) 0.085 0.256
0.6
(0.165, 1.034) 0.424 0.008
I have been vomiting 0.08(−0.054, 0.214) 0.088 0.239
0.2
(−0.1, 0.5) 0.206 0.193
When I eat, I seem to get full
quickly
0.04
(−0.148, 0.228) 0.036 0.630
0.46
(−0.037, 0.957) 0.302 0.057
My general health is
improving
0.04
(−0.148, 0.228) 0.032 0.669
0.35
(−0.095, 0.795) 0.256 0.106
I have difficulty eating rich or
“heavy” foods
0.02
(−0.187, 0.227) 0.015 0.845
0.44
(−0.038, 0.918) 0.297 0.061
A/CS, Anorexia/Cachexia Subscale; BMI, body mass index; CI, confidence interval; FAACT, Functional Assessment
of Anorexia/Cachexia Therapy.
In summary, these results on the relevant patient-reported outcomes highlight anamorelin’s
benefit over an extended period, overall and in a patient population with compounding health issues
due to progressive disease.
4. Overall Considerations
The reported improvements in LBM, combined with enhancements in total body weight, FM,
and anorexia/cachexia symptoms and concerns, suggest that anamorelin not only stimulates food
intake, but also supports its conversion into energy storage. This is among the first proof in humans
of a drug’s capacity to reverse loss of muscle tissue and LBM. Furthermore, the evident arrest of
ongoing weight loss and switch from negative to positive energy balance reported in patients from the
ROMANA trials constitutes further evidence of anamorelin’s efficacy in patients with advanced cancer
and cachexia. Importantly, the fact that anamorelin treatment results in increased body weight/LBM,
while also improving anorexia/cachexia-related symptoms and associated patient perceptions, is in
alignment with published literature from international medical community consensus that supports
body weight maintenance/gain and symptom improvement as important and meaningful treatment
goals for cancer anorexia/cachexia [26,27]. The results also bear crucial relevance, as these patients
represent an at-risk population with increased difficulty to treat as a result of their compounding
advanced disease and associated comorbidities.
5. Expert Statement
Cancer cachexia is a highly complex, multilayered syndrome, with its core consisting of the
interaction between tumor cells and the pharmacologic treatments given to control the tumor
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(Figure 2). Key cellular and soluble mediators, activated as a result of this interaction, together
with the neuroendocrine system, induce alterations in systemic metabolism and food intake. These
alterations then result in changes in the mass and functionality of various organs and tissues, which
ultimately translate into diminished QOL (Figure 2), increased morbidity, and reduced survival.
While the most efficient cancer cachexia treatment would be curing the cancer itself, which
would address all the layers detailed above, for most solid malignancies, this remains an unrealistic
goal. Furthermore, targeting the activated key mediators has also proven largely ineffective as a
result of their heterogeneity and redundancy, which renders single-mediator treatments clinically
unsuccessful. As such, the most beneficial approach is to target mechanisms [2,29], an approach
where anamorelin has the advantage of stimulating both appetite and possibly food intake, as well
as the potential to promote anabolism and, therefore, a significant gain of muscle mass (Figure 2).
In this context, the effects of anamorelin treatment on the key diagnostic features of cancer cachexia,
namely, body weight, body composition parameters, and symptom burden, bear crucial relevance.
In the ROMANA studies, mean weight increased by 1.8 kg in patients randomized to anamorelin over
12 weeks, as compared with a mean weight loss of −0.4 kg in patients randomized to placebo. Body
composition analysis suggested that anamorelin is an active anabolic agent in patients with NSCLC.
It is noteworthy that anamorelin also induced a meaningful benefit on the main patient-reported
outcome of anorexia/cachexia symptoms/concerns.
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